| Identification | Back Directory | [Name]
4,4'-(2,5-Furandiyl)bis(benzenecarboximidamide) | [CAS]
73819-26-8 | [Synonyms]
NSC 305831
FuraMidine-d8
NSC 305831-d8
2,5-Bis(4-guanylphenyl)furan
2,5-bis(4-amidinophenyl)furan
2,5-Bis(4-guanylphenyl)furan-d8
2,5-Bis(4-aMidinophenyl)furan-d8
4,4'-(2,5-Furandiyl)bis(benzenecarboximidamide)
Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis-
4-[5-(4-carbamimidoylphenyl)furan-2-yl]benzenecarboximidamide | [Molecular Formula]
C18H16N4O | [MDL Number]
MFCD01656960 | [MOL File]
73819-26-8.mol | [Molecular Weight]
304.35 |
| Hazard Information | Back Directory | [Uses]
Labelled analogue of Furamidine, a diphenylfuran compound belonging to an important class of antimicrobial and antiparasitic agents. Furamidine and its analogues also display antitumor activities and
showed antiproliferative activities against various tumor cell lines. | [in vivo]
Furamidine (1 mg/kg; intraperitoneal injection; 3 times a week and repeated every 4 weeks; for 34 weeks; female NZB/NZW mice) and Irinotecan combined treatment suppresses proteinuria and prolongs survival of lupus-prone NZB/NZW mice. The combination treatment does not change the levels of anti-dsDNA antibodies[3]. | Animal Model: | Female NZB/NZW mice (6-week-old) with Irinotecan (1 mg/kg)[3] | | Dosage: | 1 mg/kg | | Administration: | Intraperitoneal injection; 3 times a week and repeated every 4 weeks; for 34 weeks | | Result: | Suppressed proteinuria and prolongs survival of lupus-prone NZB/NZW mice combined with Irinotecan.
|
|
|
| Company Name: |
Energy Chemical
|
| Telephone: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|